Cardiometabolic & kidney

The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study

Eur J Prev CardiolPublished Secondary analysis of the FIELD randomised trial

Primary result · Total CVD events by baseline HP level (placebo group, n = 4030)Result — go to the resultHazard ratio 1.30 95% CI 1.02–1.66

Authors' conclusion

Higher baseline HP levels were associated with a higher CVD risk, especially in participants with HP 1-1 phenotype. A lower CVD risk is found only in Type 2 diabetes participants with both the HP 1-1 phenotype and low baseline HP levels. Fenofibrate benefits on CVD risk reduction did not differ by HP levels or phenotype.

Study context

Population
T2DM participants of the Fenofibrate Intervention and Event Lowering in Diabetes trial
Participants
8,047 participants
Comparison
Haptoglobin (HP) levels (tertiles) and HP phenotype; fenofibrate vs placebo by HP phenotype and levels
Primary endpoint
New on-trial total CVD events
Follow-up
5 years

Primary result

As reported in the abstract

Total CVD events by baseline HP level (placebo group, n = 4030)

Hazard ratio

1.30

95% CI 1.02–1.66

P = 0.035

Tertile 3vs Tertile 1
HR 1.30 (95% CI 1.02–1.66); P = 0.035
Association driven by participants with HP 1-1 phenotype
P for interaction = 0.011

Further findings

Cardiovascular disease (CVD) risk by HP level tertile and HP phenotype

Lowest baseline HP tertile with HP 1-1 phenotype tended to have the lowest CVD risk; risk similar in others regardless of HP phenotype and levels

Fenofibrate benefit on total CVD events by HP phenotype, baseline HP tertile, or tertile of HP change during run-in

Fenofibrate benefit did not differ significantly by HP phenotypes, baseline HP level tertiles or tertiles of HP change

Original publication

The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study. Eur J Prev Cardiol. Published 11 September 2025. doi:10.1093/eurjpc/zwaf562

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.